Big Pharma Turns to Biologics for Growth to 2010: Financial and strategic segmentation of the Big Pharma sector by drug technology
Introduction
'Big Pharma' (non-biotech companies with annual reven
April 10, 2007 (Press Release) --
Big Pharma Turns to Biologics for Growth to 2010: Financial and strategic segmentation of the Big Pharma sector by drug technology
Introduction
'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal antibodies): by 2010, annual sales of biologics will have increased by $26bn, compared to a $13bn increase for small molecules.
Scope of this report
Global sales forecasts for all Big Pharma products, split by company, therapy area and technology type, spanning the period 2001-10
Introduction to the 'technology lifecycle' concept and assignment of each of the four drug classes to distinct positions along the lifecycle
Evaluation of the competitive forces that impact the drug types, including generic exposure, access to new technology suppliers and pricing leverage
Strategic assessment of Roche's relationship with Genentech, and Novartis' contrasting approach of pursuing growth in the small molecule arena
Research and analysis highlights
Within the Big Pharma peer set, the revenue growth rate to 2010 forecast for biologics is a robust CAGR of 13.0%, outstripping the near-static CAGR of 0.9% predicted for small molecules. The small molecule growth rate is depressed by continued exposure to intense generic competition.
Big Pharma has assumed a strong position within the antibody market, a major attraction of this product type being the total absence of generic risk. In contrast, bio-similars are an emerging threat for members of the therapeutic protein class.
Roche is the leading Big Pharma player within the biologics market. It holds an extremely strong position in the antibody market thanks to its 1990 merger with Genentech. As a result, Roche is forecast to record the highest sales growth rate to 2010 within the peer set, equal to an increase in annual company sales of $14bn.
Key reasons to read this report
Understand, in dollar terms, the changing nature of product technology within 'Big Pharma' using sales forecasts through to 2010
Related Reports :
India Pharmaceutical Report
Indian Pharmaceutical Industry
Asia Generic Pharmaceuticals Forecast Report
European Pharmaceutical Logistics Market Map 2005
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=14115
Introduction
'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal antibodies): by 2010, annual sales of biologics will have increased by $26bn, compared to a $13bn increase for small molecules.
Scope of this report
Global sales forecasts for all Big Pharma products, split by company, therapy area and technology type, spanning the period 2001-10
Introduction to the 'technology lifecycle' concept and assignment of each of the four drug classes to distinct positions along the lifecycle
Evaluation of the competitive forces that impact the drug types, including generic exposure, access to new technology suppliers and pricing leverage
Strategic assessment of Roche's relationship with Genentech, and Novartis' contrasting approach of pursuing growth in the small molecule arena
Research and analysis highlights
Within the Big Pharma peer set, the revenue growth rate to 2010 forecast for biologics is a robust CAGR of 13.0%, outstripping the near-static CAGR of 0.9% predicted for small molecules. The small molecule growth rate is depressed by continued exposure to intense generic competition.
Big Pharma has assumed a strong position within the antibody market, a major attraction of this product type being the total absence of generic risk. In contrast, bio-similars are an emerging threat for members of the therapeutic protein class.
Roche is the leading Big Pharma player within the biologics market. It holds an extremely strong position in the antibody market thanks to its 1990 merger with Genentech. As a result, Roche is forecast to record the highest sales growth rate to 2010 within the peer set, equal to an increase in annual company sales of $14bn.
Key reasons to read this report
Understand, in dollar terms, the changing nature of product technology within 'Big Pharma' using sales forecasts through to 2010
Related Reports :
India Pharmaceutical Report
Indian Pharmaceutical Industry
Asia Generic Pharmaceuticals Forecast Report
European Pharmaceutical Logistics Market Map 2005
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=14115
Email
Print
SPAM
